News >

Single-Agent Acalabrutinib Showcases Potential Practice-Changing Data in Relapsed/Refractory CLL

Virginia Powers, PhD
Published: Monday, Jun 17, 2019

Paolo Ghia, MD, PhD

Chemotherapy-free treatment with single-agent acalabrutinib (Calquence) provided a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with physicians’ choice of standard therapy in patients with previously treated chronic lymphocytic leukemia (CLL), according to data from the phase III ASCEND trial that were presented at the 2019 European Hematology Association Congress.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication